Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 4/20 | 0.60 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228881 | 0.88 | PTGS1 (0.56) | PTGS1PTGS2LMNACYP1A2SLC6A2 | |
| SCHEMBL9189031 | 0.88 | CA12 (0.56) | PTGS1PTGS2LMNACYP1A2SLC6A2 | |
| SCHEMBL7141666 | 0.86 | GPR174 (0.56) | LMNACYP1A2CYP2C19MAOBGPR174 | |
| SCHEMBL15761342 | 0.85 | GPR174 (0.52) | PTGS1PTGS2LMNACYP1A2SLC6A2 | |
| SCHEMBL1486040 | 0.85 | GPR174 (0.62) | LMNAMAOBGPR174MAPTMAOA | |
| SCHEMBL2020142 | 0.83 | GPR174 (0.60) | LMNAMAOBGPR174MAPTMAOA | |
| SCHEMBL10338925 | 0.82 | GPR174 (0.58) | LMNAGPR174MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL4602806 | 0.82 | MAOB (0.70) | PTGS1PTGS2LMNACYP1A2SLC6A2 | |
| SCHEMBL20425306 | 0.82 | MAOB (0.70) | PTGS1PTGS2LMNACYP1A2SLC6A2 | |
| SCHEMBL21546008 | 0.82 | KMT2A (0.59) | LMNASLC6A2SLC6A3MAOBGPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102153562-B | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC | 2015-05-13 | — | — | CN | disclosed |
| EP-2459570-B1 | NITROIMIDAZOOXAZINE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2014-12-24 | — | — | EP | disclosed |
| US-8293734-B2 | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2459570-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | Global Alliance For Tb Drug Development (US) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011014776-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | NOX5, NQO2, SIRT5 | PTGS1 2481/4885PTGS2 1990/4885LMNA 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.